1. Introduction {#s0005}
===============

Overweight and obesity have reached epidemic proportions worldwide, for both children and adults[@bib1]. The updated World Health Organization data showed more than 1.9 billion adults aged over eighteen were overweight and over 650 million were obese in 2016, which were almost double those in 1980. Obesity always increases the risk of some complications, such as type 2 diabetes[@bib2], atherosclerosis[@bib3] and several forms of cancer[@bib4], [@bib5], [@bib6]. The mainstay anti-obesity approach remains in having low calorie diet and increasing physical activity. While, the anti-obesity therapeutic agents are the only choice for obese patients who have other comorbid conditions to restrict physical activity, such like hypertension, type 2 diabetes and arthritis. Currently, only five U. S. Food and Drug Administration-approved small molecule drugs for obesity treatment were sold on market. These anti-obesity drugs could be classified into two types, pancreatic lipase inhibitors to reduce intestinal fat absorption, and anorectics to suppress appetite. Most of them have unhappy adverse effects[@bib7]. Thus, there is still a desperate demand for effective and safe candidates to get the obesity under control.

Obesity is characterized by fat mass expansion, occurred *via* adipocytes hyperplasia (increased number of adipocytes) and hypertrophy (increased size of adipocytes), and dysfunction of adipose tissues. Under positive energy conditions, pre-adipocytes proliferate and differentiate into mature adipocytes (hyperplasia), and excessive lipid stores within adipocytes (hypertrophy). There are 3 types of adipocytes: white adipocytes store excess calories in the form of triglycerides; brown adipocytes contain large amounts of mitochondria and disperse lipids to generate heat by uncoupling protein 1 (UCP1); beige adipocytes express low UCP1 at basal status, which resemble white adipocytes, and have a highly inducible thermogenic capacity upon stimulation[@bib8], [@bib9]. Upon cold-stimulus, the sympathetic nervous system (SNS) is activated to release noradrenaline, which binds to *β*3-adrenergic receptor (*β*3-AR) on brown and beige adipocytes ([Fig. 1](#f0005){ref-type="fig"}). Subsequently, UCP1 is highly expressed and activated in mitochondria, promoting lipid *β*-oxidation and heat production ([Fig. 1](#f0005){ref-type="fig"})[@bib8]. Non-shivering thermogenesis in brown and beige adipocytes has been recognized to play a crucial role in energy balance in rodents and humans[@bib10]. Thermogenic activity of brown and beige adipocytes is positively correlated with energy expenditure, and dysregulation of thermogenesis is linked to obesity in humans[@bib11]. Studies have disclosed that the "brown" fat in human adults is composed primarily of beige adipocytes[@bib9]. Therefore, interventions to increase "brown" fat mass and/or activity are attractive strategies for prevention/treatment of obesity.Figure 1Schematic diagram of cold-activated thermogenesis. Sympathetic nerve is activated in response to cold exposure to release noradrenaline. Noradrenaline binds to the *β*3-AR on brown and beige cells to initiate signaling cascades for triglycerides hydrolysis and protein kinase A (PKA) activation. In response to PKA activation, CREB (cAMP response element-binding protein) recruits PGC-1*α* to facilitate RXR heterodimerization, which then interacts with nuclear receptors, like PPARs and LXR, to enhance *UCP1* gene transcription. Then, UCP1 dispersed the released fatty acids to generate heat.Fig. 1

Increasing evidences have revealed that thermogenic regulators have therapeutic effects towards obesity. With growing demands for treatment of obesity safely and effectively, more and more clinical studies were carried out recent years. Through searching on the data base of clinical registration in USA ([https//clinicaltrails.gov](http://https//clinicaltrails.gov){#ir0005}), 10 preparations have been involved into clinical trials ([Table 1](#t0005){ref-type="table"}). One (NCT02937298), three (NCT03171415, NCT01783470 and NCT00302276), two (NCT02048215 and NCT00302276) and four (NCT03379181, NCT03269747, NCT03189511 and NCT00781586) products have been involved in phases 1, 2, 3 and 4 clinical trials, respectively. These agents target on treatment of obesity, insulin resistance and hyperthyroidism. Till now, there is still no drug in clinic targeting thermogenesis for treatment of obesity. This review summarized recent research progresses in thermogenic regulators, and speculated their potential as anti-obesity agents.Table 1Thermogenic regulators in clinical trials.Table 1NameIdentifierConditionPhasePropranololNCT03379181Hyperthyroidism4NCT01791114Insulin sensitivity, obesity**--**PrednisoneNCT03269747BAT activity4FluvastatinNCT03189511Brown fat activity, insulin resistance4RZL-012NCT03171415Obesity2Caffeine, ephedrineNCT02048215Obesity3*β*3-AR agonistNCT01783470Obesity2CaffeineNCT00781586Energy expenditure4Zantrex-3NCT02937298Diet-induced thermogenesis, obesity**--**Metobes-compoundNCT00302276Obesity2 and 3Tyrosine, green tea, caffeineNCT02937298Diet-induced thermogenesis, obesity1[^1]

2. Thermogenic regulators targeting G protein-coupled receptors (GPCRs) {#s0010}
=======================================================================

GPCRs, a protein family comprised of more than 600 members, are associated with many physiological and pathological conditions. Thermogenic regulators targeting GPCRs have been widely investigated ([Table 2](#t0010){ref-type="table"}).Table 2Thermogenic regulators targeting GPCRs.Table 2Image 2![](fx2.gif)

2.1. *β*3-AR {#s0015}
------------

*β*3-AR, one isoform of adrenergic receptors, is pivotal in thermogenesis because it׳s selectively expressed in brown and beige adipocytes in both rodents and humans[@bib12]. Many studies have been focusing on the potential of *β*3-AR agonists as anti-obesity agents ([Table 2](#t0010){ref-type="table"}). Two *β*3-AR agonists, BRL-37344 and CL316243, were reported to induce lipolysis and thermogenesis in brown adipocytes from rats[@bib13]. CL316243 treatment increased brown adipose tissue (BAT) activity and energy expenditure of C57BL/6J mice in a thermoneutral state, but did not reduced adiposity in mice housed below thermoneutrality[@bib14]. A clinic study showed treatment of CL316243 on healthy men enhanced fat oxidation and insulin-stimulated glucose disposal[@bib15]. Acute administration of another *β*3-AR agonist, L-796568, in overweight men significantly increased energy expenditure after 4 h, while chronic administration of this compound for 4 weeks failed to increase energy expenditure[@bib16], [@bib17]. CGP-12177A is a *β*3-AR agonist, which enhanced uncoupling content in BAT and inguinal white adipose tissue (WAT) of NMRI mice[@bib18], [@bib19]. Arotinolol, a weak *β*3-AR agonist, stimulated oxygen consumption in brown adipocytes from hamsters or rats, but did not change thermogenesis in intact animals[@bib20] Mirabegron, with a high specific affinity to human *β*3-AR, is being applied to treat overactive bladder in clinic. High dose of mirabegron was reported to increase resting metabolic rate (RMR) and BAT thermogenesis in healthy young men[@bib12].

Surprisingly, several other *β*3-AR agonists, including ZD7114, ZD2079 and TAK-677, didn׳t change energy expenditure in obese humans[@bib21], [@bib22]. The failure of *β*3-AR agonists to reduce body weight or increase energy expenditure in the clinical trials might be due to the following reasons: 1) the objects, especially those obese patients, lacked brown and beige adipocytes, which led to attenuation of the effect of *β*3-AR agonists on energy expenditure; 2) the objects were treated with *β*3-AR agonists for a short period of time in the most of trials, ranging from few hours to a few days; however, the activation of BAT might be observed in a long period of time; 3) the *β*3-AR expression and function are different in rodents and humans. Most *β*3-AR agonists were authenticated to be efficient on rodents, but failed in clinical trials. The human setting from *in vitro* to *in vivo* need to be addressed. Some *β*3-AR agonists also showed adverse effects due to insufficient selectivity. The structure and function mechanism of different ARs need to be further investigated to discover and develop more specific *β*3-AR agonists as a mean of activating brown and beige adipocytes.

2.2. Adenosine receptor {#s0020}
-----------------------

The innate ligand to adenosine receptor is adenosine, which binds to four P1 GPCR subtypes, the inhibitory receptors A1 and A3 and the stimulatory receptors A~2A~ and A~2B~[@bib23]. The distribution of the adenine receptor subtypes varies greatly by tissues and species, resulting in distinct response in different tissue contexts. Adenosine and its analogues (including 2-chloroadenosine, 2′-deoxyadenosine, 3′-deoxyadenosine and 2′-deoxyadenosine monophophate) were found to inhibit isoproterenol-induced lipolysis, adenylate cyclase activation and 3′,5′-cyclic monophosphate generation in adipocytes from rodents[@bib23], [@bib24]. While, another study suggested adenosine enhanced the thermogenic program in brown and white adipocytes at nanomolar concentrations, either from human or murine; and the effect of adenosine was stronger in brown adipocytes than white adipocytes duo to higher expression of A~2A~ receptor and higher A~2A~/A1 ratio in brown adipocytes[@bib25]. These findings indicated the role of adenosine signaling in thermogenesis is still controversial, and more studies are needed.

2.3. G protein-coupled bile acid receptor (TGR5) {#s0025}
------------------------------------------------

G protein-coupled bile acid receptor, named TGR5, is involved in energy homeostasis[@bib26], [@bib27]. Administration of bile acids (BA) increased energy expenditure in BAT of mice, through inducing the cyclic adenosine monophosphate (cAMP)-dependent thyroid hormone activation[@bib28]. Interestingly, the increase of plasma BA concentration in rats was associated with the induction of genes involved in energy metabolism, including *Dio2* (iodothyronine deiodinase type 2), *Pgc-1α* (peroxisome proliferator-activated receptor *γ* coactivator-1*α*), and *UCP1*, in both BAT and abdominal and subcutaneous WAT[@bib29]. Similarly, chenodeoxycholic acid was found to increase *UCP1* expression and activate thermogenesis in human BAT[@bib30]. BA also has other hormonal actions through the farnesoid X receptor, which makes it not applicable for treatment of obesity.

3. Thermogenic regulators targeting transient receptor potential (TRP) channels {#s0030}
===============================================================================

TRP channels are a group of transmembrane cation channels that are relatively non-selective for Ca^2+^, Mg^2+^, and Na^+^ ions[@bib31]. Unlike the K^+^ selective ion channels, the TRP channels are constitutively open and are gated by a wide spectrum of physical and chemical stimuli, such as voltage, adenosine triphosphate (ATP), pH, redox agents, and multiple sensory stimuli. Upon stimulation, TRP channels initiate SNS activity, which, in turn, cascade a set of physiological processes, leading to defending responses to environmental changes. All TRP channels family members display six transmembrane *α*-helical protein domains which are assembled as tetramers to produce the overall functional channel[@bib31]. Based on sequence and topological differences, the TRP channels family are classified into seven subfamily members, the five group 1 TRPs (TRPC, TRPV, TRPM, TRPN, and TRPA) and two group 2 TRPs (TRPP and TRPML). Among them, TRPV, TRPM and TRPA belong to thermally activated members. TRPV1, TRPV2, TRPV3 and TRPV4 are for warm sensation, and TRPM8 and TRPA1 are for cold sensation.

Upon stimulation from pain, heat, cold, capsaicin, and even mechanical motion, TRP channels receptors are sufficient to activate SNS-noradrenaline-BAT axis to enhance thermogenesis[@bib32]. However, it׳s still debating whether activation or inhibition of TRP channels has benefit for thermogenesis, central or peripheral expressed TRP channels are the most critical. TRP channels regulators have received considerable attention in the field of obesity and diabetes ([Table 3](#t0015){ref-type="table"}).Table 3Thermogenic regulators targeting TRPs.Table 3Image 3Image 4![](fx3.gif)![](fx4.gif)

Capsinoids, including capsiate, dihydrocapsiate, and nordihydrocapsiate, are chemical constituents naturally present in chili peppers. In 2009, a clinical trial on healthy humans showed oral treatment with 6 mg capsinoids each day for 12 weeks caused obvious abdominal fat loss[@bib33]. In addition, administration of 4 mg/kg capsinoids for 1 month showed enhanced energy expenditure and decreased body weight[@bib34]. Another trial on healthy humans also showed that 8-week capsinoids treatment (9 mg/kg per day) increased BAT capacity using ^18^F-fluorodeoxyglucose positron emission tomography combined with computed tomography (PET-CT)[@bib35]. Through activating TRPV1 receptor, capsinoids not only enhances BAT thermogenesis, which always occurs in minutes, but also stimulates browning of WAT, which is adaptive process through increasing capacity of thermogenesis[@bib32], [@bib36]. Capsaicin, one principle constituent of hot pepper, was reported to enhance energy expenditure and fatty acid *β*-oxidation *via* stimulating TRPV1-SNS axis[@bib37]. Treatment with high dose of capsaicin (135 mg/day) for 3 months significantly increased fat oxidation without obvious adverse effect[@bib38]. Importantly, dietary capsaicin activated TRPV1-evoked Ca^2+^ influx in the process of adipocyte-to-adipocyte communication, which, in turn, promoted lipolysis both *in vitro* and *in vivo*, improving visceral fat remodeling[@bib39]. In 2011, monoacylglycerol was identified as a TRPV1 agonist, which increased *UCP1* expression in BAT and prevented visceral fat accumulation in C57BL/6Cr mice[@bib40]. 10-Oxo-12(*Z*)-octadecenoic acid, a linoleic acid metabolite produced by gut lactic acid bacteria, was reported to enhance energy metabolism by activation of TRPV1[@bib41]. A 12‐week intervention with nonivamide, a TRPV1 agonist, prevented a dietary‐induced body fat gain and increased peripheral serotonin in moderately overweight subjects[@bib42]. It is interested to note that most TRPV1 receptor agonists are constituents from edibles, such as Guinea pepper seeds, with high content, which indicate they are safe for long term application. Activation of TRPV1 may mimic chronic cold exposure to increase thermogenesis in BAT that a process for body to adapt the change of environment.

TRPV1 is a temperature sensor which gets activated at 42 °C or over. It suggests that TRPV1 is the transmitter or amplifier to thermogenesis. When initial senor gets the signal of cold and cascade a series of action to initiate thermogenesis, TRPV1 can amplify the effect of thermogenesis. TRPV2 gets activated with an activation temperature threshold of higher than 52 °C. It is notable that loss of TRPV2 in mice showed increased WAT and larger brown adipocytes, and less BAT temperature increase in response to sympathetic activation[@bib43]. However, it has been reported that activation of TRPV2 with non-selective TRPV2 agonists, 2-aminoethoxydiphenyl borate or lysophosphatidylcholine, inhibited the differentiation of mouse brown adipocytes[@bib44]. These results suggested that the role of TRPV2 in the treatment of obesity is still remaining elusive.

TRPV4 is highly expressed in adipocytes[@bib45]. Interestingly, TRPV4 expression is higher in WAT than BAT; and inactivation TRPV4 with its antagonist GSK205 led to WAT browning, while activation of TRPV4 with its agonist, GSK1016790A, repressed thermogenic genes expression[@bib46]. It inferred that inactivation of TRPV4 might stimulate the formation of beige cells in WAT. Consistently, intravenous blockade of TRPV4 channel with chemical selective antagonists, HC-067047 or RN-1734, caused an increase in core body temperature and oxygen consumption at ambient temperature of 26 °C[@bib47]. In addition, it is notable intracerebroventricular treatment with RN-1747, a chemical selective agonist of TRPV4, did not cause hypothermia. It indicated that the observed response was indeed due to activation of TRPV4 channels in the periphery[@bib47].

At lower experimental temperature like 20 °C, TRPM8 or TRPA1 is more likely to respond to cold stimulation. Previous studies have validated that TRPM8 plays a vital role in the detection of environmental temperature in mammals and is responsible for cold and chemical stimulation like menthol[@bib48], [@bib49], [@bib50]. Menthol or 1,8-cineole activates TRPM8 to trigger UCP1-induced non-shivering thermogenesis and locomotor activity[@bib51], [@bib52]. Allyl isothiocyannate and cinamaldehyde were reported to enhance thermogenesis and inhibit heat diffusion in mice, through activating TRPA1[@bib51].

There are controversial results from dietary supplementation of TRP ligands (*e.g*., capsaicin), either showing beneficial effects on body weight, metabolism, and hormone levels, or no effects. Selectivity of activators or inhibitors should be taken into consideration. Large clinical trials are needed to confirm the role of TRP ligands in the treatment of obesity. TRP channels are expressed in many tissues and organs important for the maintenance of whole body metabolism. Manipulation of TRP with small molecules is a potential strategy for induction of thermogenesis and treatment of obesity.

4. Thermogenic regulators targeting nuclear receptors in adipocyte {#s0035}
==================================================================

Nuclear receptors are a class of proteins directly binding to DNA to regulate expression of specific genes, which are highly related with energy homeostasis and metabolism[@bib53]. Thermogenic regulators targeting nuclear receptors were listed in [Table 4](#t0020){ref-type="table"}.Table 4Thermogenic regulators targeting nuclear receptors.Table 4Image 5Image 6Image 7![](fx5.gif)![](fx6.gif)![](fx7.gif)

4.1. Peroxisome proliferator-activated receptors (PPAR) {#s0040}
-------------------------------------------------------

PPARs belong to nuclear receptor super family, and so far three PPAR isoforms have been identified[@bib54]. PPAR*α* and PPAR*γ* are directly linked to thermogenesis. PPAR*δ* has capacity to increase fat acid oxidation[@bib55]. When activated by specific ligands, PPARs bind to RXR (retinoid X receptor) to form heterodimers, which translocate to nucleus and bind peroxisome proliferator response elements (PPREs) to exert its function[@bib56].

Rosiglitazone ([Table 4](#t0020){ref-type="table"}), a PPAR*γ* agonist, was found to promote mitochondrial biogenesis in 3T3-L1 adipocytes, accompanied with increased thermogenesis capacity and browning character[@bib57]. In addition, chronic treatment of rosiglitazone to human multipotent adipose-derived stem cells showed browning phenotypes by increased *UCP1* and *CIDEA* (cell death-inducing DNA fragmentation factor *α*-like effector A) mRNA expressions[@bib58]. Another study showed chronic treatment of rosiglitazone promoted browning in epididymal WAT[@bib59]. Rosiglitazone induced BAT recruitment and lipolytic mRNA levels independently of tissue innervation status[@bib60]. However, activation of PPAR*γ* by rosiglitazone strongly exacerbated cold-induced upregulation of thyroid status and *PGC-1α* and *Dio2* in BAT[@bib61]. Treatment of pioglitazone ([Table 4](#t0020){ref-type="table"}), another PPAR*γ* agonist, not only increased mitochondrial copy number but also enhanced *PGC-1α* and *TFAM* (mitochondrial transcription factor A) expressions on human subcutaneous WAT[@bib62]. PPAR pathway represented an alternative, potent, and fully competent mechanism for BAT recruitment. It is noteworthy that PPAR*γ* induced *UCP1* expression involves cross-talk between PKA (protein kinase A) and PPAR*γ* signaling systems. A study showed that rosiglitazone and forskolin synergistically activated the *UCP1* promoter involving cross-talk between the signaling systems regulating the cAMP response element (CRE) and PPRE on the promoters[@bib63]. It suggested that increasing energy expenditure *via* BAT thermogenesis maybe more potential to stimulate both PKA and PPAR*γ* signaling pathways. However, it should not be neglected that PPAR*γ* is modulated by other factors such as FGF21 (fibroblast growth factor 21)[@bib64]. Berberine ([Table 4](#t0020){ref-type="table"}) was found to increase energy expenditure and cold tolerance, and enhance BAT activity in *db/db* mice. In addition, administration of berberine led to increased expressions of *UCP1* and thermogenic genes in WAT and primary brown adipocytes *via* a mechanism involving AMPK (AMP-activated protein kinase) and PGC-1*α*[@bib65]. Collectively, PPAR*γ* activation goes prior to functioning on browning in WAT.

PPAR*α*, also known as NR1C1, is a master regulator of fatty acid oxidation, which is highly expressed in tissues consuming fatty acids at a rapid rate[@bib66]. In term of thermogenesis, PPAR*α* plays an important role in the expression of *UCP1*[@bib67]. In primary human fat cells, activation of PPAR*α* with its agonist GW7647 ([Table 4](#t0020){ref-type="table"}) resulted in up-regulation of *β*-oxidation genes and enhanced palmitate oxidation. Particularly, in this process glucose oxidation was decreased. PPAR*α* agonist may stimulate combustion of lipid instead of glucose[@bib68]. Surprisingly, thiazolidinedione treatment did not show this effect[@bib69]. In addition, PPAR*α* agonists, GW7647 or WY14643 ([Table 4](#t0020){ref-type="table"}), directly activated *PGC-1α* and *Prdm16* (PR domain containing 16) expression, resulting in induction of thermogenic genes, mitochondrial genes, and lipid oxidation genes in brown fat[@bib70]. Similarly, oleoylethanolamide ([Table 4](#t0020){ref-type="table"}), a PPAR*α* agonist, enhanced *β*3-adrenergic-mediated thermogenesis and browning in epididymal WAT in rat, with increased expressions of the mitochondrial (*Cox4i1*, *Cox4i2*), thermogenic (*FGF21*, *Prdm16*) and fatty-acid *β*-oxidation related genes[@bib71]. It suggested PPAR*α* receptor agonists promote adipocyte remodeling in epididymal WAT, and therefore have a potential clinical utility in the treatment of obesity.

PPAR*δ* is a nuclear receptor that governs a variety of biological processes, which ubiquitously distributes in brain, skin, liver, skeletal muscle and adipose tissue. It has been validated PPAR*δ* in WAT plays a role in regulating lipid mobilization and energy storage. To be frustrated, there are only few effective PPAR*δ* agonists and the mechanism remains elusive in terms of thermogenic regulation. Interestingly, previous study showed retinoic acid (RA, [Table 4](#t0020){ref-type="table"}), a vitamin A metabolite, acted as a physiological ligand of PPAR*δ*, participating in cell survival[@bib72]. RA activated PPAR*δ* in preadipocytes and adipocytes to increase *UCP1* and *Aldh9* (aldehyde dehydrogenase 9), a key enzyme in fatty acid oxidation[@bib73]. It suggested activation of PPAR*δ* shifts substrate oxidation towards combustion of lipids. In addition, administration of PPAR*δ* selective agonist GW0742 ([Table 4](#t0020){ref-type="table"}) effectively suppressed adipogenesis and enhanced lipolysis through AKT (protein kinase B) signaling pathway[@bib73].

4.2. Liver X receptors (LXR) {#s0045}
----------------------------

LXRs play a vital role in bile acid synthesis, lipid and glucose homeostasis. LXRs present in two isoforms, LXR*α* and LXR*β*. Both isoforms are expressed in mature murine and human adipocytes[@bib74]. The role of LXR in adipose tissue and obesity is still controversial, due to the complicated interaction among LXR, PPAR*γ* and C/EBP*α* (CCAAT/enhancer binding protein *α*)[@bib75], [@bib76], [@bib77]. Inhibition of LXR in BAT induced thermogenesis contributing to weight loss. Morin ([Table 4](#t0020){ref-type="table"}), a naturally occurring flavonoid, was found as an LXR*α* and LXR*β* dual antagonist, which reduced body weight gain and white adipocytes size in high fat diet (HFD)-treated mice[@bib78]. It suggested that LXR suppression has a positive correlation with thermogenesis. Consistently, a report showed TO901317 ([Table 4](#t0020){ref-type="table"}), a potent and selective LXR*α* agonist, has significant effect on suppression of *Dio2* expression in primary brown adipocytes[@bib79]. Moreover, administration of LXRs agonist GW3965 repressed UCP1 in BAT and browning of subcutaneous WAT[@bib80]. Although there are still confused findings that activation of LXRs in white adipocytes have positive correlation with fatty acid oxidation, it should be noted that all these results were obtained in white adipocytes[@bib81], [@bib82]. Interestingly, rhein ([Table 4](#t0020){ref-type="table"}), a lipophilic anthraquinone derived from a traditional Chinese herbal medicine *Rheum palmatum* L., was found to maintain energy balance by targeting LXRs and protect against obesity through LXRs-mediated *UCP1* upregulation in BAT[@bib83]. Rhein is a multitarget molecule, which still need further investigation for pharmaceutical application as an anti-obesity agent[@bib84].

4.3. Retinoid X receptor (RXR) and RA receptor (RAR) {#s0050}
----------------------------------------------------

RAR and RXR are members of the steroid/thyroid hormone receptor superfamily. RAR is activated by binding either all-*trans* RA or 9-*cis* RA ([Table 4](#t0020){ref-type="table"}); while RXR is activated only by 9-*cis* RA but not all-*trans* RA. Cellular responses to RA are mediated by RAR and RXR, which are activated to form dimeric transcriptional factors that bind to specific RA response element (RARE) to regulate thermogenesis in adipocytes[@bib85]. Twenty years ago, RA was found to activate primary brown preadipocytes, which stimulated *UCP1* gene expression through a RA-responsive region but independent of adrenergic pathway[@bib86]. Puigserver et al.[@bib87] firstly reported that administration of all-*trans*-RA or 9-*cis*-RA led to an increase in the BAT specific UCP1 content in mice, as well as in HIB1B brown adipocytes. Dietary vitamin A ([Table 4](#t0020){ref-type="table"}) supplementation increased *UCP1* expression in BAT of mice[@bib88]. Feeding a vitamin A-deficient diet triggered opposite effects to those of all-*trans*-RA treatment, including increased body weight and reduced BAT thermogenic potential[@bib89]. In addition, either synthetic RAR-specific agonist, *p*-\[(*E*)-2-(5,6,7,8,-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl\]benzoic acid ([Table 4](#t0020){ref-type="table"}), or RXR-specific agonist, methoprene ([Table 4](#t0020){ref-type="table"}), increased the expression of *UCP1* mRNA and the activity of chloramphenicol acetyltransferase expression vectors driven by the *UCP1* promoter[@bib90]. It indicated both RAR- and RXR-dependent signaling pathways mediate the induction of *UCP1* in BAT by retinoids. It is noteworthy that RA׳s effects on induction of UCP1 might associate with p38 mitogen-activated protein kinase (p38MAPK) activation. Inhibition of p38MAPK activity with PD169316 hindered retinoid on induction of UCP1, suggesting p38MAPK participating in this process[@bib91]. RA suppressed adipogenesis *in vivo* by activating the cellular PPAR*δ* associated binding proteins cellular RA binding protein type II (CRABP-II)/RAR*γ* path in preadipocytes[@bib92]. These findings indicated RA as common dietary supplements help to counteract diet-induced obesity. Fenretinide ([Table 4](#t0020){ref-type="table"}), a synthetic retinoid, was found to prevent obesity and insulin resistance in HFD-fed mice and completely suppress 3T3-L1 preadipocyte differentiation[@bib93]. It is promising to apply RAR agonist to counteract diet-induced obesity. It has been reported that all-*trans* RA induced UCP1 expression in mouse white and brown adipocytes, but not in human adipocyte cell lines or primary human white adipocytes[@bib94]. More studies on human adipocytes are needed to verify RAs as thermogenesis inducers.

4.4. Vitamin D receptor {#s0055}
-----------------------

The vitamin D receptor (VDR), a member of the steroid/thyroid/retinoid nuclear receptor superfamily, dimerizes with RXR*α*, and binds to VDR response elements (VDREs). It was reported that VDR is expressed in adipose tissue and dynamically up-regulated during adipocytes differentiation[@bib95], [@bib96]. The hormonal form of vitamin D, 1,25-dihydroxy vitamin D3 ([Table 4](#t0020){ref-type="table"}), suppressed the expression of *UCP1*[@bib97], and vitamin D or VDR deficiency decreased adiposity and increased UCP1 in rodents[@bib98], [@bib99], [@bib100], [@bib101]. In addition, adipocytes from humans with hereditary vitamin D resistant rickets showed increased UCP1 expression and a browning phenotype[@bib102]. To be frustrated, there is no data reported about VDR antagonist on thermogenesis. On the other hand, vitamin D׳s positive effect on adipogenesis might be suitable for some special populations like cachexia patients.

4.5. Pregnane X receptor {#s0060}
------------------------

The primary function of pregnane X receptor (PXR) is to sense the presence of xenobiotic substances and respond to detoxification and clearance of these substances from the body[@bib103]. PXR activation is associated with thermogenesis[@bib104]. Pregnenolone 16*α*-carbonitrile ([Table 4](#t0020){ref-type="table"}) enhanced thermogenesis by induction the mRNA expression of *Dio2*, *PGC-1α*, *PGC-1β* and Cidea in BAT of mice[@bib105]. However, there was no significant increase in *UCP1* mRNA in adipocytes. The mechanism of PXR on thermogenesis is still unclear.

4.6. Estrogen receptors (ERs) {#s0065}
-----------------------------

The rat, mouse and human ERs exist as two subtypes, ER*α* and ER*β*[@bib106]. A decade ago, 17*β*-estradiol was found to promote mitochondrial biogenesis and thermogenic function in primary brown adipocytes[@bib107]. It is notable that 17*β*-estradiol negatively modulated the ATP synthase activity through direct binding to the oligomycin sensitive-conferring protein[@bib108], which may result in decreasing of mitochondrial ATP generation. ERs are highly expressed in the hypothalamus[@bib109] and estradiol upregulated BAT thermogenesis *via* hypothalamic AMPK[@bib110]. In the brown fat, diethylstilbestrol increased the expression of *Bmp8b* (bone morphogenetic protein 8b) and *FGF* family genes involved in BAT activity[@bib111]. A 3-day-treatment with a selective ER*β* agonist, LY3201 ([Table 4](#t0020){ref-type="table"}), induced browning of subcutaneous abdominal fat pad in obese female mice[@bib112]. Consistently, acute 17*β*-estradiol or estradiol benzoate ([Table 4](#t0020){ref-type="table"}) treatment led to thermogenesis in female sheep but not chronic estrogen treatment[@bib113]. One possible explanation was that the distribution of ER subtypes varies by tissues and species, resulting in distinct response in different tissue contexts. Taken together, a stable estrogen level or ER agonist is essential to keep thermogenesis in BAT and energy homeostasis in female.

5. Miscellaneous {#s0070}
================

Some other small molecules have also been reported to induce thermogenesis ([Table 5](#t0025){ref-type="table"}).Table 5Miscellaneous small molecules inducing thermogenesis.Table 5Image 8![](fx8.gif)

Phosphodiesterases (PDEs) hydrolyze cGMP (cyclic guanosine monophosphate) and cAMP. Chronic treatment with sildenafil, a PDE-5 inhibitor, resulted in increased energy expenditure[@bib114]. Surprisingly, the *UCP1* level was significantly lower in BAT from sildenafil-treated mice[@bib114]. While, short-term sildenafil treatment showed no change on *UCP1* or *PGC-1α* levels in BAT; however, it caused an increase of *UCP1* and *PGC-1α* expressions in WAT and browning features like appearance of multilocular adipocytes within WAT[@bib115]. It suggested that beige cells are responsible for sildenafil induced thermogenesis.

FAS (fatty acid synthase) is a multi-enzyme protein that catalyzes fatty acid synthesis, especially the synthesis of palmitate. Inhibition of FAS by its inhibitor C75 activated sympathetic outflow and thermogenesis in BAT, indicating FAS might serve as a potential target of thermogenesis[@bib116].

Low dosage of *trans*-10, *cis*-12 conjugated linoleic acid (CLA) increased browning in overweight SV129 mice. CLA led to reduction in percentage of body fat, and increased *UCP1* level and fatty acid oxidation[@bib117], [@bib118] 12,13-Dihydroxy-9*Z*-octadecenoic acid (12,13-diHOME), a lipid to stimulate BAT activity, is negatively correlated with body-mass index. A study showed the injection of 12,13-diHOME activated BAT fuel uptake, enhanced cold tolerance and decreased levels of serum triglycerides through promoting the membrane translocation of the fatty acid transporters fatty acid transport protein 1 and CD36[@bib119]. The identification of BAT-specific lipid utilization may spark potential way to unlock the maximum therapeutic potential of brown fat in humans. *R*-(+)-citronellal and *β*-citronellol from citronella oil, one of the most famous Indonesian essential oils, have ability to increase temperature and sympathetic nerve activity in BAT[@bib120]. In another study, the major component of *Zingiber zerumbet*, zerumbone, was found to enhance sympathetic nerve activity and temperature in BAT[@bib121]. Some oral anti-diabetic drugs showed thermogenic effect. Miglitol, *α*-glucosidase inhibitor, was able to increase energy expenditure by upregulating UCP1 in BAT. Miglitol has capability in enhancement of *β*3-adrenergic signaling[@bib122]. However, it needs further investigation to fully elucidate the thermogenic effect of miglitol. Another study showed paradol analogues increased energy metabolism in the BAT *via* the activation of sympathetic nerve activity; and the length of the acyl chain of the paradol analogues had a significant impact on the extent of UCP1 expression level[@bib123]. Using a transgenic animal model expressing luciferase to mimics endogenous UCP1 expression, a potential modulator WWL113 was discovered with capacity to increase UCP1 expression and thermogenic response without significant change in locomotor activity, food intake, or heartbeat[@bib124]. Resveratrol increased energy expenditure and the expression of thermogenic markers through activating SIRT1 (silent mating type information regulation 2 homolog 1)[@bib125]. However, another group reported resveratrol induced thermogenesis through SIRT1 independent pathway[@bib126]. The role of SIRT1 in resveratrol induced thermogenesis remains elusive. Experiments using transgenic mice overexpressing UCP1 in metabolic tissues showed that locally uncoupling oxidative phosphorylation (OXPHOS) could combat obesity[@bib127]. A novel chemical uncoupler, CZ5, was found to elevate energy expenditure without change *UCP1* level[@bib128].

6. Conclusions {#s0075}
==============

Direct ways to evaluate thermogenic capacity are mainly comprised of determination of expressions of thermogenic genes, oxygen consumption rate and mitochondrial function in brown adipocytes, as well as measurement of core temperature, locomotor activity, energy expenditure and sympathetic nerve activity in animals. Each the above method has limitation; and results from one or few assays might cause misleading. A systemic evaluation including *in vitro* and *in vivo* models should be carried out to authenticate thermogenic regulators.

UCP proteins are able to mediate directly adaptive non-shivering thermogenesis and metabolic inefficiency[@bib129], [@bib130], [@bib131]. Among them, UCP1 protein is the most important marker to predict thermogenesis capacity. At the mitochondrial inner membrane, the energy of nutrients such as glucose and lipids is converted into a proton gradient, but instead of storing the potential energy in the generation of ATP, UCP1 catalyzes an inducible proton leak to release the energy of the proton gradient directly as heat. It should be noted that UCP1 does not primarily evolve as an anti-obesity protein but as a means of quickly generating heat. Over-activated UCP1 posed a threat on thermogenic response when confronted with acute cold stimulation. Activation of UCP1 is not an automatic process and requires extra stimulation such as hormones, chemical agents, nutritional or even environmental factors. Therefore, additional variables including housing temperature, mouse strain and diet should be accurately controlled. No exact evidence showed there is a definite link between the expression of UCP1 and basal brown adipocyte metabolic rate. On the contrary, a previous work showed enhancement in UCP1 expression was accompanied with no difference in basal energy expenditure[@bib124]. To analyze thermogenic capacity, measurements of UCP1 at both mRNA and protein levels with functional and metabolic assessments are necessary.

There are some indications of alternative uncoupling mechanisms besides UCP1, such as the creatine kinase cycle[@bib132] and calcium cycle[@bib133]. UCP1 knockdown animals was found to be acclimated to cold temperature[@bib134] and WAT contributes to UCP1-independent thermogenesis[@bib135]. Evidences have showed that beige cells have higher respiratory capacity than brown adipocytes, which are supposed to occupy high level of UCP1[@bib9]. In addition, beige cells express beige-selective marker, TMEM26 (transmembrane protein 26), CD137, and other thermogenic markers including mitochondrial genes *Cox7a1* and *Cox8b*, transcriptional coregulatory PRDM16 and PGC-1*β*, and the thermogenic hormone FGF21[@bib9]. Using a brown adipocyte culture system, PPAR activation was found to represent a nonadrenergic, potent, and fully competent mechanism for BAT recruitment[@bib59]. The complementary ways to increase energy expenditure in BAT remain to be unexplored.

The major brown fat deposits in adult humans are composed of beige adipocytes, which express distinct gene profiles[@bib9]. It׳s also notable that classic brown fat exists in adult human, mainly distributes in the cervical, supraclavicular, axillary, and paravertebral regions; it may be involved in protecting the brain by warming up the blood supplied to the brain[@bib136]. While, greater proportion of brown adipocytes and less proportion of beige cells exist in adult rodents. Most of the thermogenic regulators in previous studies were investigated on either *in vitro* brown adipocytes or *in vivo* murine models. It might explain why some thermogenic inducers did not show activity in humans. Human WAT derived beige cells should be recruited to screen thermoregulatory molecules and investigate underlying mechanisms. The content and function of brown adipocytes and the beige cells are declined with age, contributing to an obesity-prone character in aged objects[@bib10], [@bib137]. The design of clinical trials in future need to include a broader age range, both genders, and diverse genetic or ethnic backgrounds to reveal important information for stratified therapeutic approaches.

Uncontrolled thermogenic treatments can produce excessive heat, promote cachexia, and muscle waste, similar to victims of severe burns and cancer[@bib138]. Thus, developing pharmacological brakes for thermogenesis also has an important therapeutic value.

There are a constantly expanding numbers of regulatory nodes and pathways that integrate BAT function with physiological changes. Some endogenous molecules have been identified to control thermogenesis. The increasing levels of key endogenous molecules, such as irisin and FGF21, are associated with metabolically beneficial in obese states, which might be potential targets of some of the molecules described in this review. The metabolic changes in certain disease states are disproportionately inhibiting thermogenesis; thus, identifying the molecular pathways other than thermogenesis is likely to supply new therapeutic opportunities.

The allosteric regulation triggering the protein׳s functional activity *via* conformational changes is an intrinsic function of protein under many physiological and pathological conditions, including metabolism[@bib139], [@bib140]. Protein-tyrosine phosphatase 1B (PTP1B) is the prototype for the superfamily of PTPs involving in regulation of insulin, leptin and adiponectin to govern food intake and energy metabolism[@bib141]. Either a whole-body or whole-brain deletion of PTP1B causes lean, leptin-hypersensitive and resistant to HFD-induced obesity in mice[@bib142], [@bib143]. PTP1B allosteric inhibitors prevent formation of the active form of PTP1B by blocking mobility of the catalytic loop, thereby exploiting a general mechanism used by tyrosine phosphatases[@bib144]. However, it remains elusive how PTP1B allosteric inhibition regulates energy metabolism. Modern allosteric drug discovery faces considerable challenges; in particular, there is the vast majority of allosteric sites in proteins which are undiscovered[@bib145], [@bib146]. Thus, the allosteric regulation might be a potential pathway for discovery of thermogenic regulators.

The key for the medicinal utilization of small molecules targeting thermogenesis is specificity and efficacy. The unique qualities of brown adipocytes with unique regulatory systems will help address the issue of specificity. It׳s more difficult to elucidate the complex central regulatory mechanisms that sense heat production and modulate sympathetic nervous stimulation of thermogenesis. There should be key nuclei that integrate information on temperature and energy availability, which might be specific targets to control BAT activation. The approaches of thermogenic regulation at multiple levels are likely to be the most effective.

Given the growing world-wide prevalence and increasing healthcare burden of obesity and associated diseases and the current lack of effective treatment strategies, new anti-obesity therapies are urgently needed. Emerging evidences have indicated BAT, mostly beige adipocytes, is present in human adults, and activation of BAT is inversely associated with obesity and metabolic disease. In either rodent models or clinical trials, several pharmacological approaches increasing thermogenic capacity have been proven to effectively prevent obesity, facilitate weight reduction, and ameliorate insulin resistance. Although, there are still many issues to be solved for the therapeutic agents targeting activation or expansion of BAT, including: 1) the effectiveness of a thermogenic enhancer in treating obesity and insulin resistance is still unstable; 2) compensating mechanisms, such as increased appetite, could reduce the benefits of this approach; 3) the risks of drugs in central nervous system and sympathetic nerve activation should also be considered. The pharmacological approaches targeting stimulation of BAT activity and increase of energy expenditure would provide exciting new options in obesity therapy.
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